Lessons learned from cancer vaccine trials and target antigen choice
about
Advances in immunotherapy for melanoma management.Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.In silico prediction of cancer immunogens: current state of the art.
P2860
Lessons learned from cancer vaccine trials and target antigen choice
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lessons learned from cancer vaccine trials and target antigen choice
@en
Lessons learned from cancer vaccine trials and target antigen choice.
@nl
type
label
Lessons learned from cancer vaccine trials and target antigen choice
@en
Lessons learned from cancer vaccine trials and target antigen choice.
@nl
prefLabel
Lessons learned from cancer vaccine trials and target antigen choice
@en
Lessons learned from cancer vaccine trials and target antigen choice.
@nl
P2860
P1476
Lessons learned from cancer vaccine trials and target antigen choice
@en
P2093
Lisa H Butterfield
P2860
P2888
P304
P356
10.1007/S00262-016-1801-1
P577
2016-02-03T00:00:00Z